Rodman & Renshaw See 243% Upside In OncoSec Medical Shares


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Rodman & Renshaw initiated coverage on OncoSec Medical Inc

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

(NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain.

According to the analysts, several near-term value drivers could constitute meaningful upside to their estimates. "We currently only model sales of ImmunoPulse™ IL-12 in melanoma, without factoring in contributions from other potential therapeutic candidates generated by OncoSec's proprietary technology platform or possible applications in other indications, such as triple-negative breast cancer (TNBC)," the analysts wrote.

They also mentioned three major risks to their valuation, including (1) negative trial data, (2) failure to show synergy with approved immunotherapy drugs, (3) regulatory delays or rejections.

Full ratings data available on Benzinga Pro.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com with the story link to let us know!


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: Analyst ColorBiotechLong IdeasHealth CarePrice TargetInitiationAnalyst RatingsTrading IdeasGeneralcancerImmunotherapyoncologyRodman & Renshaw